The Characteristics of Renal Cell Carcinoma Patients, Who may Benefit from Radiotherapy and Post-Nephrectomy

Author： Zarzycka Małgorzata   Wolski Zbigniew   Makarewicz Roman   Windorbska Wiesława  

Publisher： Ashgate Publishing Ltd

ISSN： 1561-0950

Source： UroOncology, Vol.3, Iss.3-4, 2003-01, pp. : 99-105

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

En Bloc Adrenalectomy as Part of Radical Nephrectomy for Renal Cell Carcinoma. Is it Justified?

By Adshead J.M.   Livni N.   Christmas T.J.  

UroOncology, Vol. 2, Iss. 2, 2002-01 ,pp. : 95-97

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Patients with relapsed or refractory mantle cell lymphoma may receive benefit from bortezomib

By  

Inpharma, Vol. 1, Iss. 1544, 2006-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Patient Benefit-Risk Preferences for Targeted Agents in the Treatment of Renal Cell Carcinoma

By Mohamed Ateesha F.  

PharmacoEconomics, Vol. 29, Iss. 11, 2011-11 ,pp. : 977-988

Adis International

Access to resources Recommend Favorite

B-cell lymphoma vaccination may benefit certain patients with NHL

By  

Inpharma, Vol. 1, Iss. 1475, 2005-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Pretreatment measurement of Bcl-2 expression may identify those who might benefit from taxane-based chemotherapy

By  

Inpharma, Vol. 1, Iss. 1567, 2006-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite